PMID- 28419059
OWN - NLM
STAT- MEDLINE
DCOM- 20180424
LR  - 20220331
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 27
IP  - 4
DP  - 2017 Aug
TI  - Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple 
      immune-related adverse events.
PG  - 391-395
LID - 10.1097/CMR.0000000000000355 [doi]
AB  - Immune-related adverse effects (AEs) of PD-1 inhibitors can affect almost every 
      organ, but the skin, intestine, lung, eye, and liver are the most commonly 
      affected organs. Here, we present the case of a 62-year-old female patient with 
      stage IIIc melanoma treated with nivolumab in an adjuvant setting who 
      sequentially developed hyperthyroidism, hypothyroidism, acute hepatitis, and 
      pneumonitis. Six months before the emergence of pneumonitis, the patient had 
      discontinued treatment with nivolumab because of acute hepatitis. Information on 
      pneumonitis after nivolumab discontinuation in the literature is scarce, whereas 
      most of the cases emerge during the first 2.5 months of treatment. Patients with 
      multiple immune-related AEs comprise a group of special interest as the 
      identification of factors affecting the susceptibility of patients to 
      immune-related AEs of PD-1 inhibitors may lead to a more rational use of these 
      drugs. Human leukocyte antigen haplotype and Fcgamma receptor polymorphisms are 
      possible targets of the relevant research.
FAU - Diamantopoulos, Panagiotis T
AU  - Diamantopoulos PT
AD  - aFirst Department of Internal Medicine, National and Kapodistrian University of 
      Athens bDepartment of Pneumology, Laikon General Hospital, Athens, Greece.
FAU - Gaggadi, Maria
AU  - Gaggadi M
FAU - Kassi, Eva
AU  - Kassi E
FAU - Benopoulou, Olga
AU  - Benopoulou O
FAU - Anastasopoulou, Amalia
AU  - Anastasopoulou A
FAU - Gogas, Helen
AU  - Gogas H
LA  - eng
PT  - Journal Article
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Antibodies, Monoclonal/*adverse effects/pharmacology
MH  - Antineoplastic Agents/*adverse effects/pharmacology
MH  - Female
MH  - Humans
MH  - Melanoma/*drug therapy/pathology
MH  - Middle Aged
MH  - Nivolumab
MH  - Pneumonia/*chemically induced
MH  - Skin Neoplasms/*drug therapy/pathology
EDAT- 2017/04/19 06:00
MHDA- 2018/04/25 06:00
CRDT- 2017/04/19 06:00
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/04/25 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
AID - 10.1097/CMR.0000000000000355 [doi]
PST - ppublish
SO  - Melanoma Res. 2017 Aug;27(4):391-395. doi: 10.1097/CMR.0000000000000355.